358 related articles for article (PubMed ID: 24038328)
21. CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.
Zinzow-Kramer WM; Long AB; Youngblood BA; Rosenthal KM; Butler R; Mohammed AU; Skountzou I; Ahmed R; Evavold BD; Boss JM
Genes Immun; 2012 Jun; 13(4):299-310. PubMed ID: 22218223
[TBL] [Abstract][Full Text] [Related]
22. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
[TBL] [Abstract][Full Text] [Related]
23. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes--class II MHC, Ii and H-2M. Class II TransActivator.
Kielar ML; Sicher SC; Penfield JG; Jeyarajah DR; Lu CY
Inflammation; 2000 Oct; 24(5):431-45. PubMed ID: 10921507
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.
Ghorpade DS; Holla S; Sinha AY; Alagesan SK; Balaji KN
J Biol Chem; 2013 Jul; 288(28):20592-606. PubMed ID: 23733190
[TBL] [Abstract][Full Text] [Related]
26. Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.
Patel DR; Li W; Park JS; Sofi MH; Gourley TS; Hangoc G; Kaplan MH; Chang CH
Cell Immunol; 2005 Jan; 233(1):30-40. PubMed ID: 15876426
[TBL] [Abstract][Full Text] [Related]
27. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.
Piskurich JF; Gilbert CA; Ashley BD; Zhao M; Chen H; Wu J; Bolick SC; Wright KL
Mol Immunol; 2006 Feb; 43(6):519-28. PubMed ID: 15950283
[TBL] [Abstract][Full Text] [Related]
28. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes.
Otten LA; Tacchini-Cottier F; Lohoff M; Annunziato F; Cosmi L; Scarpellino L; Louis J; Steimle V; Reith W; Acha-Orbea H
J Immunol; 2003 Feb; 170(3):1150-7. PubMed ID: 12538670
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
30. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells.
Chou SD; Khan AN; Magner WJ; Tomasi TB
Int Immunol; 2005 Nov; 17(11):1483-94. PubMed ID: 16210330
[TBL] [Abstract][Full Text] [Related]
31. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
[TBL] [Abstract][Full Text] [Related]
32. Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases.
Yau AC; Piehl F; Olsson T; Holmdahl R
Immunology; 2017 Apr; 150(4):408-417. PubMed ID: 27861821
[TBL] [Abstract][Full Text] [Related]
33. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
34. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III.
Holling TM; van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Jan; 168(2):763-70. PubMed ID: 11777970
[TBL] [Abstract][Full Text] [Related]
35. Expression of MHC II genes.
Drozina G; Kohoutek J; Jabrane-Ferrat N; Peterlin BM
Curr Top Microbiol Immunol; 2005; 290():147-70. PubMed ID: 16480042
[TBL] [Abstract][Full Text] [Related]
36. ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.
Yoon HS; Scharer CD; Majumder P; Davis CW; Butler R; Zinzow-Kramer W; Skountzou I; Koutsonanos DG; Ahmed R; Boss JM
J Immunol; 2012 Sep; 189(5):2393-403. PubMed ID: 22851713
[TBL] [Abstract][Full Text] [Related]
37. The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription.
Fan Z; Kong X; Xia J; Wu X; Li H; Xu H; Fang M; Xu Y
Biochim Biophys Acta; 2016 May; 1859(5):687-96. PubMed ID: 26972221
[TBL] [Abstract][Full Text] [Related]
38. Prolonged survival of class II transactivator-deficient cardiac allografts.
June Brickey W; Felix NJ; Griffiths R; Zhang J; Wang B; Piskurich JF; Itoh-Lindstrom Y; Coffman TM; Ting JP
Transplantation; 2002 Nov; 74(9):1341-8. PubMed ID: 12451276
[TBL] [Abstract][Full Text] [Related]
39. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
40. Highly efficient peptide binding and T cell activation by MHC class II molecules of CIITA-transfected cells.
Martinez-Soria E; Siegrist CA; Mach B
Int Immunol; 1996 Apr; 8(4):543-9. PubMed ID: 8671641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
